Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Taohong Siwu Decoction is a modified Traditional Chinese Medicine (TCM) herbal formula based on the classic Taohong Siwu Decoction (Peach Kernel and Safflower Four-Substance Decoction). It is primarily investigated for its potential in treating severe non-proliferative diabetic retinopathy (NPDR). The base formula, Taohong Siwu, is traditionally used to "activate blood and resolve stasis," a therapeutic principle aimed at improving microcirculation and reducing vascular permeability. The "Jiawei" (modified) version typically includes additional herbs tailored to the specific pathology of diabetic complications, such as those targeting Qi or Yin deficiency. In clinical research, it is often evaluated as an adjuvant therapy alongside standard treatments like laser photocoagulation to mitigate retinal ischemia and hypoxia-induced damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jiawei taohong siwu decoction.